"Do Tregitopes have the potential to impact the current treatment lands" by Anne S. De Groot
 

Document Type

Article

Date of Original Version

12-2013

Abstract

Current treatment of autoimmune disease usually involves the use of cytotoxic drugs or biologic agents that interfere with the activity of B cells, T cells or key cytokines, such as TNF, IL-1 and IL-6. On occasion, polyclonal immunoglobulin G (IgG), intravenous (IVIg) is used. The discovery of IgG- (and hence IVIg-) derived T regulatory (Treg) epitopes that trigger the expansion of Tregs in vitro and in vivo provides a novel explanation for the effect of IVIg. These IgG-derived Treg epitopes (also known as Tregitopes) appear to be effective on their own (in vivo, in autoimmune disease models) and when co-administered with a specific autoimmune disease antigen, contribute to antigen-specific tolerance induction. A description of Tregitopes and a brief discussion of their potential applications in autoimmune disease are provided here. Tregitope-based immunotherapy has the potential to modify the current autoimmune pharmacopeia.

Plum Print visual indicator of research metrics
PlumX Metrics
  • Citations
    • Citation Indexes: 7
  • Usage
    • Downloads: 291
    • Abstract Views: 83
  • Captures
    • Readers: 18
see details

Share

COinS